Abstract
There is, today, great need for new systems and strategies for therapeutic applications that will lead to improvements in patient conditions and prognoses, especially in complex diseases such as neurodegenerative diseases and cancer. Recently, polymer nanocarriers have been developed to protect and transport active compounds to pathological sites more efficiently than free compounds in terms of stability, amount required, localization and efficacy. There are two strategies to deliver active compounds: conventional drug delivery systems based on transport and release of active compounds in biological compartments and nanoreactors that transport active compounds and permit them to act in situ, behaving like rudimentary artificial organelles. Here, we present both strategies with their advantages and limitations, and indicate how they can contribute to therapeutic improvement. We focus on presenting the design and development of polymer nanocarriers and nanoreactors as an essential stage of conceiving therapeutic approaches. The properties of the polymer carrier and its behavior under biological conditions dramatically influence the efficacy of the active compound, and thus of the treatment scheme. The key contributions that nanocarriers and nanoreactors could make include protecting active compounds from degradation in biological compartments other than those desired, and concentrating such compounds within their assemblage to allow for multiple deliveries in one single polymer assembly. To efficiently cope with the challenges of complex pathological conditions it is necessary to go one step beyond conventional drug delivery systems by designing and developing nanocarriers that mimic organelles, by combining various active molecules in a single carrier, and even by combining therapeutic agents along with agents for detection, as in a theragnostic approach.
Keywords: Polymeric nanocarriers, nanoreactors, neurodegenerative diseases, cancer, drug delivery, efficacy, active compounds, polymer assembly, drug delivery systems, organelles
Current Pharmaceutical Design
Title:Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Volume: 18 Issue: 18
Author(s): Ozana Onaca-Fischer, Juan Liu, Mark Inglin and Cornelia G. Palivan
Affiliation:
Keywords: Polymeric nanocarriers, nanoreactors, neurodegenerative diseases, cancer, drug delivery, efficacy, active compounds, polymer assembly, drug delivery systems, organelles
Abstract: There is, today, great need for new systems and strategies for therapeutic applications that will lead to improvements in patient conditions and prognoses, especially in complex diseases such as neurodegenerative diseases and cancer. Recently, polymer nanocarriers have been developed to protect and transport active compounds to pathological sites more efficiently than free compounds in terms of stability, amount required, localization and efficacy. There are two strategies to deliver active compounds: conventional drug delivery systems based on transport and release of active compounds in biological compartments and nanoreactors that transport active compounds and permit them to act in situ, behaving like rudimentary artificial organelles. Here, we present both strategies with their advantages and limitations, and indicate how they can contribute to therapeutic improvement. We focus on presenting the design and development of polymer nanocarriers and nanoreactors as an essential stage of conceiving therapeutic approaches. The properties of the polymer carrier and its behavior under biological conditions dramatically influence the efficacy of the active compound, and thus of the treatment scheme. The key contributions that nanocarriers and nanoreactors could make include protecting active compounds from degradation in biological compartments other than those desired, and concentrating such compounds within their assemblage to allow for multiple deliveries in one single polymer assembly. To efficiently cope with the challenges of complex pathological conditions it is necessary to go one step beyond conventional drug delivery systems by designing and developing nanocarriers that mimic organelles, by combining various active molecules in a single carrier, and even by combining therapeutic agents along with agents for detection, as in a theragnostic approach.
Export Options
About this article
Cite this article as:
Onaca-Fischer Ozana, Liu Juan, Inglin Mark and G. Palivan Cornelia, Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications, Current Pharmaceutical Design 2012; 18 (18) . https://dx.doi.org/10.2174/138161212800492822
DOI https://dx.doi.org/10.2174/138161212800492822 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Benzamide Riboside, a Recent Inhibitor of Inosine 5-Monophosphate Dehydrogenase Induces Transferrin Receptors in Cancer Cells
Current Medicinal Chemistry Potential Targets for Improving Radiosensitivity of Breast Tumor-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Human Neural Stem and Progenitor Cells: In Vitro and In Vivo Properties, and Potential for Gene Therapy and Cell Replacement in the CNS
Current Gene Therapy Oxidovanadium(IV) Complex Disrupts Mitochondrial Membrane Potential and Induces Apoptosis in Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy TGF-ß / Smad Signaling in Prostate Cancer
Current Drug Targets Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research Friend or Foe: UCHL3 Mediated Carcinogenesis and Current Approaches in Small Molecule Inhibitors’ Development
Current Medicinal Chemistry Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Differences in Phosphorylated Histone H2AX Foci Formation and Removal of Cells Exposed to Low and High Linear Energy Transfer Radiation
Current Genomics Drug Repositioning for Treatment of Movement Disorders: From Serendipity to Rational Discovery Strategies
Current Topics in Medicinal Chemistry Vascular microRNAs
Current Drug Targets Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design Towards the Development of Tumor Necrosis Factor (TNF) Sensitizers:Making TNF Work Against Cancer
Current Pharmaceutical Design Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Nose to Brain Delivery: New Trends in Amphiphile-Based “Soft” Nanocarriers
Current Pharmaceutical Design Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry